CYBB and fatty liver disease: Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, diminished HFD-induced fatty liver accompanied by a suppression of RAGE and inflammatory cytokines and this effect was reversed by overexpression of NOX2 [301].